WO2003020898A2 - Reseaux comprenant des molecules biologiques pre-marquees et methodes de fabrication et d'utilisation de ces reseaux - Google Patents

Reseaux comprenant des molecules biologiques pre-marquees et methodes de fabrication et d'utilisation de ces reseaux Download PDF

Info

Publication number
WO2003020898A2
WO2003020898A2 PCT/US2002/027743 US0227743W WO03020898A2 WO 2003020898 A2 WO2003020898 A2 WO 2003020898A2 US 0227743 W US0227743 W US 0227743W WO 03020898 A2 WO03020898 A2 WO 03020898A2
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
anay
array
cloned
detectable label
Prior art date
Application number
PCT/US2002/027743
Other languages
English (en)
Other versions
WO2003020898A3 (fr
Inventor
Shishir Shah
Mansoor Mohammed
Original Assignee
Spectral Genomics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectral Genomics, Inc. filed Critical Spectral Genomics, Inc.
Priority to US10/488,492 priority Critical patent/US20050032060A1/en
Priority to AU2002331777A priority patent/AU2002331777A1/en
Publication of WO2003020898A2 publication Critical patent/WO2003020898A2/fr
Publication of WO2003020898A3 publication Critical patent/WO2003020898A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00497—Features relating to the solid phase supports
    • B01J2219/005—Beads
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00497—Features relating to the solid phase supports
    • B01J2219/00511—Walls of reactor vessels
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00497—Features relating to the solid phase supports
    • B01J2219/00513—Essentially linear supports
    • B01J2219/00515—Essentially linear supports in the shape of strings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00497—Features relating to the solid phase supports
    • B01J2219/00527—Sheets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/0054—Means for coding or tagging the apparatus or the reagents
    • B01J2219/00572—Chemical means
    • B01J2219/00576—Chemical means fluorophore
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00585—Parallel processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00596—Solid-phase processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00612—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports the surface being inorganic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00639—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium
    • B01J2219/00641—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium the porous medium being continuous, e.g. porous oxide substrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00659—Two-dimensional arrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00677—Ex-situ synthesis followed by deposition on the substrate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/0068—Means for controlling the apparatus of the process
    • B01J2219/00686—Automatic
    • B01J2219/00689—Automatic using computers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00722—Nucleotides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00725—Peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00731—Saccharides

Definitions

  • This invention relates to molecular biology, genetic diagnostics and array, or "biochip,” technology.
  • the invention provides novel arrays, particularly nucleic acid arrays, comprising a plurality of biological molecules, wherein each biological molecule is immobilized to a discrete and known spot on a substrate surface to fonn an array of biological molecules, and each biological molecule comprises a detectable label.
  • Genomic DNA microanay based comparative genomic hybridization has the potential to solve many of the limitations of traditional CGH method, which relies on comparative hybridization on individual metaphase chromosomes.
  • CGH genomic DNA microanay based comparative genomic hybridization
  • metaphase CGH multi-megabase fragments of different samples of genomic DNA (e.g., known normal versus test, e.g., a possible tumor) are labeled and hybridized to a fixed chromosome (see, e.g., Breen (1999) J. Med. Genetics 36:511-517; Rice (2000) Pediatric Hematol. Oncol. 17:141- 147).
  • the invention provides an array comprising a plurality of biological molecules, wherein each biological molecule is immobilized to a discrete and known spot on a substrate surface to form an array of biological molecules, and each biological molecule comprises a detectable label.
  • the biological molecule comprises a nucleic acid, e.g., an oligonucleotide, a lipid, a polysaccharide, a polypeptide (e.g., a peptide), or an analog or a mimetic thereof, or a combination thereof.
  • the nucleic acid can comprise a DNA (e.g., a genomic DNA or a cDNA), an RNA (e.g., an mRNA, rRNA, and the like) or an analog or a mimetic thereof or a combination thereof.
  • the nucleic acid can further comprise a telomeric structure or a chromatin structure. Analogs and mimetics can include small molecules, as discussed below.
  • the biological molecule e.g., the biological molecule, e.g., a nucleic acid
  • the biological molecule is derived from a mammal, e.g., a human.
  • the nucleic acids can be genomic DNA or can be derived from a genomic DNA.
  • the nucleic acids can comprise cloned nucleic acid segments, such as cloned genomic nucleic acid segments.
  • the cloned genomic nucleic acid segments are free of deletions, as compared to a corresponding wild type genomic nucleic acid segment.
  • the cloned genomic nucleic acid segment can be free of additions, as compared to a conesponding wild type genomic nucleic acid segment.
  • the cloned genomic nucleic acid segment can be free of additions and deletions, as compared to a corresponding wild type genomic nucleic acid segment.
  • the cloned genomic nucleic acid segment comprises a gene, a cDNA or a DNA sequence corresponding to or complementary to an RNA message.
  • the message can comprise sequence encoding a polypeptide.
  • each spot (on a substrate surface) consists of a plurality of nucleic acids comprising a single cloned genomic nucleic acid segment.
  • the cloned genomic nucleic acid segments in a first spot are non- overlapping in sequence compared to the cloned genomic nucleic acid segments in a second spot.
  • the cloned genomic nucleic acid segments in a spot are non-overlapping in sequence compared to the cloned genomic nucleic acid segments all of other genomic nucleic acid-comprising spots on the array.
  • each cloned genomic nucleic acid segment is spotted in duplicate or triplicate on the anay.
  • the cloned genomic nucleic acid segments together can comprise a known segment of a genome.
  • the known segment of a genome can comprise a substantially complete chromosome, such as a mammalian chromosome, e.g., a human chromosome.
  • the known segment of a genome can comprise a substantially complete genome, such as a mammalian genome, e.g., a human genome.
  • the cloned nucleic acid segment is cloned in a construct comprising an artificial chromosome, such as a bacterial artificial chromosome (BAC), a human artificial chromosome (HAC) a yeast artificial chromosome (YAC), a transformation- competent artificial chromosome (TAC) or a bacteriophage PI -derived artificial chromosome (PAC).
  • an artificial chromosome such as a bacterial artificial chromosome (BAC), a human artificial chromosome (HAC) a yeast artificial chromosome (YAC), a transformation- competent artificial chromosome (TAC) or a bacteriophage PI -derived artificial chromosome (PAC).
  • BAC bacterial artificial chromosome
  • HAC human artificial chromosome
  • YAC yeast artificial chromosome
  • TAC transformation- competent artificial chromosome
  • PAC bacteriophage PI -derived artificial chromosome
  • the cloned nucleic acid segment is between about 5 kilobases (0.05 megabase) to about 1000 kilobases (10 megabases) in length, between about 50 kilobases (0.5 megabase) to about 500 kilobases (5 megabases) in length, between about 100 kilobases (1 megabase) to about 400 kilobases (4 megabases) in length, and about 300 kilobases (3 megabases) in length.
  • the detectable label comprises a fluorescent label, such as a Cy5TM or equivalent, a Cy3TM or equivalents; and, a rhodamine, a fluorescein or an aryl- substituted 4,4-difluoro-4-bora-3a, 4a-diaza-s-indacene dye or equivalents.
  • the biological molecule is covalently and non-covalently bound to the detectable label.
  • labels also can be incorporated into the biological molecule, as with labeled nucleosides incorporated into a nucleic acid by, e.g., nick translation, random primer extension, amplification with degenerate primers (by, e.g., PCR), and the like.
  • all of the array-immobilized biological molecules comprise the same detectable label.
  • a biological molecule also can comprise two or more labels, or, two or more labels can be associated with the array-immobilized biological molecules.
  • about 50%, about 60%, about 70%, about 80%, about 90%, about 95%o, about 99%), or 100% of the array-immobilized biological molecules comprise at least one detectable label.
  • some biological molecules on a "spot” can be unlabeled, i.e., it is not necessary that all of the biological molecules on a "spot” be labeled, hi another aspect, an array can have “spots" of biological molecules that are not labeled, or, are differently labeled as compared to the same biological molecules on other spots on the array.
  • the biological molecule is covalently and non- covalently bound to the substrate surface.
  • the biological molecule is covalently bound to a compound having the general formula: Ri — X — R 2 , wherein Ri is a cyclic ether, an aldehyde, or a chloromethylphenyl moiety; X is a moiety chemically suitable for linking the Ri moiety to the R 2 moiety, and the R 2 moiety has the general formula
  • R 3 , i and R 5 comprise identical or different alkoxy group or chloro groups.
  • the cyclic ether can be an epoxide group.
  • the epoxide group can be an epoxycyclohexyl group or epoxycyclopentyl group.
  • the R 2 moiety can comprise an alkoxysilane group.
  • the R 2 moiety can be selected from the group consisting of a methoxyethoxy group, a -OCH 2 CH 2 OCH 3 group, a chlorohalide group and a propoxy group.
  • the Ri — X — R 2 compound can be selected from the group consisting of (3- glycidoxypropyl) methyldiethoxysilane, (3-glycidoxypropyl) methyldiisopropenoxy-silane; 2-(3,4-epoxycyclohexyl)ethyltrimethoxysilane and (3-glycidoxypropyl) dimethylethoxysilane.
  • the biological molecule is covalently bound to a compound having the general formula: Ri — X — R 2 , wherein Ri is an amino group, R is an alkoxysilane group or a chlorohalide group; and X is a moiety chemically suitable for linking the Ri group and the R 2 group.
  • the biological molecule is covalently bound to a compound having the general formula
  • R — X — Si (OR 2 ) m (Cl)don (R) k , [0021] wherein m + k is the integer 3 , and n canbe O ifm is greater than 0, or n + k is the integer 3 and m can be 0 if n is greater than 0; X is an inert linker; Ri comprises a group reactive toward the biological molecule; R is an alkyl group; and, R 2 is an alkyl group.
  • the invention provides an anay comprising a plurality of bacterial artificial chromosomes (BACs), wherein each bacterial artificial chromosome is immobilized to a discrete and known spot on a substrate surface to form an array of bacterial artificial chromosomes (BACs), and each bacterial artificial chromosome comprises a detectable label.
  • the array can comprise a SpectralChipTM Mouse BAG Array.
  • the array can comprise a SpectralChipTM Human BAG Anay.
  • the invention provides a method of making an array, wherein the array comprises a plurality of genomic nucleic acids covalently labeled with a compound comprising a fluorescent label, comprising the following steps (a) providing plurality of genomic nucleic acid segments, wherein the segments have lengths averaging between about 0.5 megabase and about 5 megabases or are fragmented or digested to have lengths averaging between about 0.5 megabase and about 5 megabases; (b) labeling the genomic nucleic acid segments of step (a) with a fluorescent label; and, (c) immobilizing the random prime labeled nucleic acids to discrete and known spots on a substrate surface to form an array of nucleic acids.
  • the cloned nucleic acid segment is cloned in a construct comprising an artificial chromosome, such as a bacterial artificial chromosome (BAG), a yeast artificial chromosome (YAC), a human artificial chromosome (HAC), a bacteriophage PI -derived artificial chromosome (PAC), or, a cosmid or a plasmid.
  • an artificial chromosome such as a bacterial artificial chromosome (BAG), a yeast artificial chromosome (YAC), a human artificial chromosome (HAC), a bacteriophage PI -derived artificial chromosome (PAC), or, a cosmid or a plasmid.
  • the detectable label comprises a fluorescent label.
  • the fluorescent label comprises Cy5TM or equivalent, a Cy3TM or equivalent, or, a rhodamine, a fluorescein or an aryl-substituted 4,4-difluoro-4-bora-3a, 4a-diaza-s-indacene dye or equivalents.
  • the labeling of the nucleic acid segments comprises random prime labeling, nick translation labeling, amplification with degenerate primers (by, e.g., PCR), and the like.
  • the invention provides a method of performing comparative genomic hybridization (CGH) using an array comprising a plurality of genomic nucleic acids covalently labeled with a compound comprising a detectable label, comprising the following steps: (a) providing an anay comprising a plurality of cloned genomic nucleic acid segments, wherein each genomic nucleic acid segment is immobilized to a discrete and known spot on a substrate surface to form an array, and the genomic nucleic acid segments comprise a first detectable label; (b) providing a sample comprising a plurality of genomic nucleic acid segments, wherein the sample genomic nucleic acid segments are labeled with at least a second detectable label; (c) contacting the sample of step (b) with the array of step (a) under conditions wherein the nucleic acid in the sample can specifically hybridize to the genomic nucleic acid segments of step (a); and, (d) measuring the amount of first and second fluorescent label on each spot, thereby performing comparative genomic hybridization.
  • the cloned nucleic acid segment is cloned in a construct comprising an artificial chromosome, such as a bacterial artificial chromosome (BAC), YAC, HAC, PI, and the like.
  • the detectable label comprises a fluorescent label, such as a Cy5TM or equivalent, a Cy3TM or equivalent, or, a rhodamine, a fluorescein or an aryl- substituted 4,4-difluoro-4-bora-3a, 4a-diaza-s-indacene dye or equivalents.
  • the invention provides a method of comparing copy numbers of unique nucleic acid sequences in a first sample comprising nucleic acid of a cell or cell population relative to copy numbers of substantially identical sequences in at least a second sample comprising nucleic acid of at least a second cell or cell population, said method comprising the steps of: (a) providing an array comprising the nucleic acid of a first sample, wherein the nucleic acid is immobilized to discrete and known spots on a substrate surface to form an anay, and the nucleic acids of a first sample comprise a first detectable label; (b) providing a second sample comprising nucleic acid labeled with a second detectable label; (c) contacting the sample of step (b) with the array of step (a) under conditions wherein the nucleic acid in the sample can specifically hybridize to the immobilized nucleic acid of step (a); and, (d) comparing the intensities of the signals from the labeled sample nucleic acids hybridized to the immobilized nu
  • the invention provides a multiplexed system for performing comparative genomic hybridization (CGH) using an anay comprising: (a) an array comprising a plurality of biological molecules, wherein each biological molecule is immobilized to a discrete and known spot on a substrate surface to form an array of biological molecules, and each biological molecule comprises a first detectable label; (b) a device for detecting the array- immobilized detectable label and at least one second detectable label, wherein the device can measure which detectable labels are on which spots on the substrate surface.
  • the device of step (b) comprises a charge-coupled device (CCD).
  • Figure 1 is a schematic illustration of an exemplary humidified hybridization chamber and an unbalanced humidity hybridization format of the invention.
  • the invention provides novel methods and compositions for array-based nucleic acid hybridizations. New methods and compositions are provided for generating a molecular profile of genomic DNA by hybridization of a target nucleic acid derived from genomic DNA to an immobilized nucleic acid probe, e.g., as in an "anay-based comparative genomic hybridization (CGH)."
  • CGH comparative genomic hybridization
  • the invention provides an anay comprising a plurality of biological molecules, such as genomic DNA, wherein each biological molecule is immobilized to a discrete and known spot on a substrate surface to form an array of biological molecules, and each immobilized biological molecule comprises a detectable label.
  • a detectable label can be used to label the molecules immobilized on the array.
  • the sample of biological molecules is labeled with one or more detectable labels that are different from the one or more detectable moieties used to label the molecules immobilized on the array.
  • the invention provides a method for generating a molecular profile of one or more genomes, or a defined portion of a genome, e.g., a chromosome or part of a chromosome, by hybridization of target nucleic acid derived from a genomic DNA to an immobilized nucleic acid probe(s), e.g., in the form of an array.
  • the method comprises contacting the (labeled) immobilized nucleic acid segment (e.g., cloned DNA) with a sample of target nucleic acid comprising fragments of genomic nucleic acid labeled with a detectable moiety.
  • aryl-substituted 4,4-difluoro-4-bora-3a, 4a-diaza-s-indacene dye as used herein includes all “boron dipynomethene difluoride fluorophore” or “BODIPY” dyes and "dipynometheneboron difluoride dyes” (see, e.g., U.S. Patent No. 4,774,339), or equivalents, are a class of fluorescent dyes commonly used to label nucleic acids for their detection when used in hybridization reactions; see, e.g., Chen (2000) J. Org Chem. 65:2900- 2906: Chen (2000) J. Biochem. Biophys.
  • fluorescent dye includes all known fluors, including rhodamine dyes (e.g., tetramethylrhodamine, dibenzorhodamine, see, e.g., U.S. Patent No. 6,051,719); fluorescein dyes; "BODIPY” dyes and equivalents (e.g., dipyrrometheneboron difluoride dyes, see, e.g., U.S. Patent No. 5,274,113); derivatives of l-[isoindolyl]methylene- isoindole (see, e.g., U.S. Patent No. 5,433,896); and all equivalents. See also U.S. Patent Nos. 6,028,190; 5,188,934.
  • hybridizing specifically to and “specific hybridization” and “selectively hybridize to,” as used herein refer to the binding, duplexing, or hybridizing of a nucleic acid molecule preferentially to a particular nucleotide sequence under stringent conditions.
  • stringent conditions refers to conditions under which a probe will hybridize preferentially to its target subsequence, and to a lesser extent to, or not at all to, other sequences.
  • a “stringent hybridization” and “stringent hybridization wash conditions” in the context of nucleic acid hybridization are sequence dependent, and are different under different environmental parameters.
  • Stringent hybridization conditions that can be used to identify nucleic acids can include, e.g., hybridization in a buffer comprising 50%> formamide, 5x SSC, and 1% SDS at 42°C, or hybridization in a buffer comprising 5x SSC and 1% SDS at 65°C, both with a wash of 0.2x SSC and 0.1% SDS at 65°C.
  • Exemplary stringent hybridization conditions can also include a hybridization in a buffer of 40% formamide, 1 M NaCl, and 1% SDS at 37°C, and a wash in IX SSC at 45°C.
  • Those of ordinary skill will readily recognize that alternative but comparable hybridization and wash conditions can be utilized to provide conditions of similar stringency.
  • wash conditions used to identify nucleic acids include, e.g.: a salt concentration of about 0.02 molar at pH 7 and a temperature of at least about 50°C or about
  • the hybridization complex is washed twice with a solution with a salt concentration of about 2X SSC containing 0.1% SDS at room temperature for 15 minutes and then washed twice by 0.1X SSC containing 0.1%
  • Stringent conditions for washing can also be, e.g., 0.2 X SSC/0.1 % SDS at 42°C.
  • stringent conditions can include washing in
  • labeled with a detectable composition refers to a biological molecule, e.g., a polypeptide or a nucleic acid, comprising a detectable composition, i.e., a label, as described in detail, below.
  • the label can also be another biological molecule, as a nucleic acid, e.g., a nucleic acid in the form of a stem-loop structure as a "molecular beacon,” as described below.
  • labeled bases or, bases which can bind to a detectable label
  • the label can be detectable by any means, e.g., visual, spectroscopic, photochemical, biochemical, immunochemical, physical or chemical means.
  • the invention provides arrays comprising immobilized biological molecules, e.g., nucleic acids, comprising detectable labels.
  • genomic DNA means detection of regions of amplification, deletions and/ or unique sequences in a test sample of nucleic acid representing a genomic DNA as compared to a control (e.g., "normal") sample of DNA.
  • Genetic DNA or “genomic nucleic acid” includes sense and complementary strands, cloned and amplified copies, synthetic copies, or otherwise reproduced sequences of a genomic nucleic acid.
  • nucleic acid refers to a deoxyribonucleotide or ribonucleotide in either single- or double-stranded form.
  • the term encompasses nucleic acids containing known analogues of natural nucleotides.
  • the term also encompasses nucleic-acidlike structures with synthetic backbones.
  • DNA backbone analogues provided by the invention include phosphodiester, phosphorothioate, phosphorodithioate, methylphosphonate, phosphoramidate, alkyl phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino), 3'- N-carbamate, morpholino carbamate, and peptide nucleic acids (PNAs); see Ohgonucleotides and Analogues, a Practical Approach, edited by F. Eckstein, IRL Press at Oxford University Press (1991); Antisense Strategies, Annals of the New York Academy of Sciences, Volume 600, Eds. Baserga and Denhardt (NYAS 1992); Milligan (1993) J. Med. Chem.
  • PNAs contain non-ionic backbones, such as N-(2-aminoethyl) glycine units. Phosphorothioate linkages are described, e.g., by U.S. Patent Nos. 6,031,092; 6,001,982; 5,684,148; see also, WO 97/03211; WO 96/39154; Mata (1997) Toxicol. Appl. Pharmacol. 144:189-197.
  • Other synthetic backbones encompassed by the term include methyl-phosphonate linkages or alternating methylphosphonate and phosphodiester linkages (see, e.g., U.S. Patent No.
  • nucleic acid is used interchangeably with gene, DNA, RNA, cDNA, mRNA, oligonucleotide primer, probe and amplification product.
  • polypeptide include compositions of the invention that also include “analogs,” or “conservative variants” and “mimetics” or “peptidomimetics” with structures and activity that substantially conespond to the polypeptide from which the variant was derived, as discussed in detail, below.
  • small molecule means any synthetic small molecule, such as an organic molecule or a synthetic molecule, such as those generated by combinatorial chemistry methodologies. These small molecules can be synthesized using a variety of procedures and methodologies, which are well described in the scientific and patent literature, e.g., Organic Syntheses Collective Volumes, Gifman et al.
  • anay or “microarray” or “DNA array” or “nucleic acid array” or “biochip” as used herein is a plurality of target elements, each target element comprising a defined amount of one or more biological molecules, e.g., nucleic acids, immobilized a solid surface for hybridization to sample biological molecules, e.g., nucleic acids.
  • sample of nucleic acid targets or “sample of nucleic acid” as used herein refers to a sample comprising DNA or RNA, or nucleic acid representative of DNA or RNA isolated from a natural source, in a form suitable for hybridization (e.g., as a soluble aqueous solution) to another nucleic acid or polypeptide or combination thereof (e.g., immobilized probes).
  • the nucleic acid may be isolated, cloned or amplified; it may be, e.g., genomic DNA, mRNA, or cDNA from substantially an entire genome, substantially all or part of a particular chromosome, or selected sequences (e.g.
  • the nucleic acid sample may be extracted from particular cells or tissues.
  • the cell or tissue sample from which the nucleic acid sample is prepared is typically taken from a patient suspected of having a genetic defect or a genetically-linked pathology or condition, e.g., a cancer, associated with genomic nucleic acid base substitutions, amplifications, deletions and/or translocations.
  • Methods of isolating cell and tissue samples are well known to those of skill in the art and include, but are not limited to, aspirations, tissue sections, needle biopsies, and the like.
  • the sample will be a "clinical sample” which is a sample derived from a patient, including sections of tissues such as frozen sections or paraffin sections taken for histological purposes.
  • the sample can also be derived from supernatants (of cells) or the cells themselves from cell cultures, cells from tissue culture and other media in which it may be desirable to detect chromosomal abnormalities or determine amplicon copy number.
  • the nucleic acids may be amplified using standard techniques such as PCR, prior to the hybridization.
  • the immobilized biological molecule is labeled, as described herein.
  • the probe an be produced from and collectively can be representative of a source of nucleic acids from one or more particular (pre-selected) portions of, e.g., a collection of polymerase chain reaction (PCR) amplification products, substantially an entire chromosome or a chromosome fragment, or substantially an entire genome, e.g., as a collection of clones, e.g., BACs, PACs, YACs, and the like (see below).
  • PCR polymerase chain reaction
  • the probe or genomic nucleic acid sample may be processed in some manner, e.g., by blocking or removal of repetitive nucleic acids or by enrichment with selected nucleic acids.
  • a computer/ processor can be a conventional general-purpose digital computer, e.g., a personal "workstation” computer, including conventional elements such as microprocessor and data transfer bus.
  • the computer / processor can further include any form of memory elements, such as dynamic random access memory, flash memory or the like, or mass storage such as magnetic disc optional storage.
  • the invention provides nucleic acid arrays and methods for performing nucleic acid hybridization reactions.
  • the target nucleic acid for analysis and the immobilized nucleic acid on the anay can be representative of genomic DNA, including defined parts of, or entire, chromosomes, or entire genomes.
  • the arrays and methods of the invention are used in comparative genomic hybridization (CGH) reactions; see, e.g., U.S. Patent Nos. 5,830,645; 5,976,790.
  • CGH comparative genomic hybridization
  • test samples e.g., whether a test sample of genomic DNA (e.g., from a cell suspected of having a genetic defect) has amplified or deleted or mutated segments, as compared to a "negative" control, e.g., "normal” wild type genotype, or "positive” control, e.g., known cancer cell or cell with a known defect, e.g., a translocation or amplification or the like.
  • a test sample of genomic DNA e.g., from a cell suspected of having a genetic defect
  • positive control e.g., known cancer cell or cell with a known defect, e.g., a translocation or amplification or the like.
  • the test sample comprises fragments of nucleic acid representative of defined parts of a chromosome or genome, or the entire genome.
  • the test sample also can be labeled, e.g., with a detectable moiety, e.g., a fluorescent dye.
  • the test sample nucleic acid can labeled with a fluor and the control (e.g., "normal") sample is labeled with a second dye (e.g., Cy3TM and Cy5TM).
  • the sample nucleic acid is labeled with different detectable moieties, e.g., different fluorescent dyes, than those used to label the immobilized nucleic acids.
  • Test and control samples are both applied to the immobilized probes (e.g., on the array) and, after hybridization and washing, the location (e.g., spots on the array) and amount of each dye are read.
  • the immobilized nucleic acid can be representative of any part of or all of a chromosome or genome. If immobilized to an array, this nucleic acid can be in the form of cloned DNA, e.g., YACs, BACs, PACs, and the like, as described herein. As is typical of array technology, each "spot" on the array has a known sequence, e.g., a known segment of genome or other sequence.
  • the invention can be practiced in conjunction with any method or protocol or device known in the art, which are well described in the scientific and patent literature.
  • RNA, cDNA, genomic DNA, vectors, viruses or hybrids thereof may be isolated from a variety of sources, genetically engineered, amplified, and/or expressed/ generated recombinantly. Any recombinant expression system can be used, including, in addition to bacterial cells, e.g., mammalian, yeast, insect or plant cell expression systems.
  • these nucleic acids can be synthesized in vitro by well-known chemical synthesis techniques, as described in, e.g., Carrathers (1982) Cold Spring Harbor Symp. Quant. Biol. 47:411-418; Adams (1983) J. Am. Chem. Soc. 105:661; Belousov (1997) Nucleic Acids Res. 25:3440-3444; Frenkel (1995) Free Radic. Biol. Med. 19:373-380; Blommers (1994) Biochemistry 33:7886-7896; Narang (1979) Meth. Enzymol. 68:90; Brown (1979) Meth. Enzymol. 68:109; Beaucage (1981) Tetra. Lett.
  • Double stranded DNA fragments may then be obtained either by synthesizing the complementary strand and annealing the strands together under appropriate conditions, or by adding the complementary strand using DNA polymerase with a primer sequence.
  • nucleic acids such as, e.g., subcloning, labeling probes (e.g., random-primer labeling using Klenow polymerase, nick translation, amplification), sequencing, hybridization and the like are well described in the scientific and patent literature, see, e.g., Sambrook, ed., MOLECULAR CLONING: A LABORATORY MANUAL (2ND ED.), Vols. 1-3, Cold Spring Harbor Laboratory, (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Ausubel, ed.
  • genomic nucleic acid used in the methods and compositions of the invention includes genomic or cDNA libraries contained in, or comprised entirely of, e.g., mammalian artificial chromosomes (see, e.g., Ascenzioni (1997) Cancer Lett. 118:135-142; U.S. Patent Nos.
  • BACs are vectors that can contain 120 Kb or greater inserts. BACs are based on the E. coli F factor plasmid system and simple to manipulate and purify in microgram quantities. Because BAC plasmids are kept at one to two copies per cell, the problems of rearrangement observed with YACs, which can also be employed in the present methods, are eliminated; see, e.g., Asakawa (1997) Gene 69-79; Cao (1999) Genome Res. 9:763-774.
  • BAC vectors can include marker genes, such as, e.g., luciferase and green fluorescent protein genes (see, e.g., Baker (1997) Nucleic Acids Res 25:1950-1956).
  • YACS can also be used and contain inserts ranging in size from 80 to 700 kb, see, e.g., Tucker (1997) Gene 199:25-30; Adam (1997) Plant 111:1349-1358; Zeschnigk (1999) Nucleic Acids Res. 27:21 .
  • PI is a bacteriophage that infects E.
  • Amplification using oligonucleotide primers can be used to generate nucleic acids used in the compositions and methods of the invention, to incorporate label into immobilized or sample nucleic acids, to detect or measure levels of test or control samples hybridized to an array, and the like.
  • Amplification typically with degenerate primers, is also useful for incorporating detectable probes (e.g., Cy5TM- or Cy3TM-cytosine conjugates) into nucleic acids representative of test or control genomic DNA to be used to hybridize to immobilized genomic DNA.
  • detectable probes e.g., Cy5TM- or Cy3TM-cytosine conjugates
  • the skilled artisan can select and design suitable oligonucleotide amplification primers.
  • Amplification methods are also well known in the art, and include, e.g., polymerase chain reaction, PCR (PCR PROTOCOLS, A GUIDE TO METHODS AND
  • Probes 10:257-271) and other RNA polymerase mediated techniques e.g., NASBA, Cangene, Mississauga, Ontario); see also Berger (1987) Methods Enzymol. 152:307-316; Sambrook; Ausubel; U.S. Patent Nos. 4,683,195 and 4,683,202; Sooknanan (1995) Biotechnology 13:563-564. See, e.g., U.S. Patent No. 6,063,571, describing use of polyamide-nucleic acid derivatives (PNAs) in amplification primers.
  • PNAs polyamide-nucleic acid derivatives
  • test and control samples of nucleic acid are hybridized to immobilized probe nucleic acid, e.g., on anays.
  • the hybridization and/or wash conditions are carried out under moderate to stringent conditions.
  • An extensive guide to the hybridization of nucleic acids is found in, e.g., Sambrook Ausubel, Tijssen.
  • highly stringent hybridization and wash conditions are selected to be about 5°C lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength and pH.
  • the T m is the temperature (under defined ionic strength and pH) at which 50%> of the target sequence hybridizes to a perfectly matched probe.
  • Very stringent conditions are selected to be equal to the T m for a particular probe.
  • An example of stringent hybridization conditions for hybridization of complementary nucleic acids which have more than 100 complementary residues on an array or a filter in a Southern or northern blot is 42°C using standard hybridization solutions (see, e.g., Sambrook), with the hybridization being carried out overnight.
  • An example of highly stringent wash conditions is 0.15 M NaCl at 72°C for about
  • An example of stringent wash conditions is a 0.2x SSC wash at 65°C for 15 minutes (see, e.g., Sambrook). Often, a high stringency wash is preceded by a medium or low stringency wash to remove background probe signal.
  • An example medium stringency wash for a duplex of, e.g., more than 100 nucleotides, is lx SSC at 45°C for 15 minutes.
  • An example of a low stringency wash for a duplex of, e.g., more than 100 nucleotides, is 4x to 6x
  • the fluorescent dyes Cy3TM and Cy5TM are used to differentially label nucleic acid fragments from two samples, e.g., the array-immobilized nucleic acid versus the sample nucleic acid, or, nucleic acid generated from a control versus a test cell or tissue.
  • Many commercial instruments are designed to accommodate to detection of these two dyes.
  • antioxidants and free radical scavengers can be used in hybridization mixes, the hybridization and/or the wash solutions.
  • Cy5TM signals are dramatically increased and longer hybridization times are possible. See co- pending U.S. Patent Application Serial No. 09/839,658, filed 4/19/01.
  • hybridization can be carried out in a controlled, unsaturated humidity environment; thus, hybridization efficiency is significantly improved if the humidity is not saturated. See co-pending U.S. Patent Application Serial No. 09/839,658, filed 4/19/01.
  • the hybridization efficiency can be improved if the humidity is dynamically controlled, i.e., if the humidity changes during hybridization. Mass transfer will be facilitated in a dynamically balanced humidity environment.
  • the humidity in the hybridization environment can be adjusted stepwise or continuously.
  • Array devices comprising housings and controls that allow the operator to control the humidity during pre-hybridization, hybridization, wash and/or detection stages can be used.
  • the device can have detection, control and memory components to allow preprogramming of the humidity (and temperature (see below), and other parameters) during the entire procedural cycle, including pre-hybridization, hybridization, wash and detection steps. See co-pending U.S. Patent Application Serial No. 09/839,658, filed 4/19/01.
  • Figure 1 is a schematic illustration of an exemplary humidified hybridization chamber and an unbalanced humidity hybridization format of the invention.
  • the methods of the invention can incorporate hybridization conditions comprising temperature fluctuation.
  • Hybridization has much better efficiency in a changing temperature environment as compared to conditions where the temperature is set precisely or at relatively constant level (e.g., plus or minus a couple of degrees, as with most commercial ovens).
  • Reaction chamber temperatures can be fluctuatingly modified by, e.g., an oven, or other device capable of creating changing temperatures. See co-pending U.S. Patent Application Serial No. 09/839,658, filed 4/19/01.
  • the methods of the invention can comprise hybridization conditions comprising osmotic fluctuation.
  • Hybridization efficiency i.e., time to equilibrium
  • a hybridization environment that comprises changing hyper-/hypo-tonicity, e.g., a solute gradient.
  • a solute gradient is created in the device. For example, a low salt hybridization solution is placed on one side of the array hybridization chamber and a higher salt buffer is placed on the other side to generate a solute gradient in the chamber. See co-pending U.S. Patent Application Serial No. 09/839,658, filed 4/19/01. Polyp eptides
  • the invention is also directed to anays comprising labeled immobilized polypeptides, peptides and peptidomimetics.
  • the polypeptides, peptides and peptidomimetics can be immobilized to a substrate surface using any methodology, including covalent or non-covalent, direct or indirect, attachment to a surface.
  • a polypeptide can be modified by reaction with a compound having the formula: Ri — X — R 2 , where Ri is a cyclic ether group or an amino group, R is an alkoxysilane group and X is a moiety chemically suitable for linking the cyclic ether group or the amino group to the alkoxysilane group.
  • polypeptide As noted above, the terms “polypeptide,” “protein,” and “peptide,” used to practice the invention, include compositions of the invention that also include “analogs,” or “conservative variants” and “mimetics” or “peptidomimetics.”
  • mimetic and “peptidomimetic” refer to a synthetic chemical compounds.
  • the mimetic can be either entirely composed of synthetic, non-natural analogues of amino acids, or, is a chimeric molecule of partly natural peptide amino acids and partly non-natural analogs of amino acids.
  • the mimetic can also incorporate any amount of natural amino acid conservative substitutions as long as such substitutions also do not substantially alter the mimetics' structure and or activity.
  • Polypeptide mimetic compositions can contain any combination of non-natural structural components, which are typically from three structural groups: a) residue linkage groups other than the natural amide bond ("peptide bond") linkages; b) non-natural residues in place of naturally occurring amino acid residues; or c) residues which induce secondary structural mimicry, i.e., to induce or stabilize a secondary structure, e.g., a beta turn, gamma turn, beta sheet, alpha helix conformation, and the like.
  • a secondary structural mimicry i.e., to induce or stabilize a secondary structure, e.g., a beta turn, gamma turn, beta sheet, alpha helix conformation, and the like.
  • a polypeptide can be characterized as a mimetic when all or some of its residues are joined by chemical means other than natural peptide bonds, individual peptidomimetic residues can be joined by peptide bonds, other chemical bonds or coupling means, such as, e.g., glutaraldehyde, N-hydroxysuccinimide esters, bifunctional maleimides, N,N'- dicyclohexylcarbodiimide (DCC) or N,N'-diisopropylcarbodiimide (DIG).
  • DCC dicyclohexylcarbodiimide
  • DIG N,N'-diisopropylcarbodiimide
  • a polypeptide can also be characterized as a mimetic by containing all or some non-natural residues in place of naturally occurring amino acid residues; non- natural residues are well described in the scientific and patent literature.
  • the skilled artisan will recognize that individual synthetic residues and polypeptides incorporating mimetics can be synthesized using a variety of procedures and methodologies, which are well described in the scientific and patent literature, e.g., Organic Syntheses Collective Volumes, Gihnan, et al., supra.
  • Polypeptides incorporating mimetics can also be made using solid phase synthetic procedures, as described, e.g., by U.S. Pat. No.
  • Peptides and peptide mimetics can also be synthesized using combinatorial methodologies.
  • Various techniques for generation of peptide and peptidomimetic libraries are well known, and include, e.g., al-Obeidi (1998) Mol. Biotechnol. 9:205-223; Hruby (1997) Curr. Opin. Chem. Biol. 1:114-119; Ostergaard (1997) Mol. Divers. 3:17-27; Ostresh (1996) Methods Enzymol. 267:220-234.
  • Modified polypeptide and peptides can be further produced by chemical modification methods, see, e.g., Belousov (1997) Nucleic Acids Res. 25:3440-3444; Frenkel (1995) Free Radic. Biol. Med. 19:373-380; Blommers (1994) Biochemistry 33:7886-7896.
  • These peptides can also be synthesized, whole or in part, using chemical methods well known in the art (see e.g., Caruthers (1980) Nucleic Acids Res. Symp. Ser. 215-223; Horn (1980) Nucleic Acids Res. Symp. Ser.
  • the invention provides improved variations of "anays” or “microarrays” or
  • DNA arrays or “nucleic acid arrays” or “biochips.”
  • the present invention can be practiced with any known array, or variation thereof.
  • Arrays are generically a plurality of "target elements," each target element comprising a defined amount of one or more biological molecules, e.g., polypeptides, nucleic acid molecules, or probes, immobilized a solid surface for specific binding, e.g., hybridization, to sample molecules.
  • Immobilized nucleic acids can contain sequences from specific messages (e.g., as cDNA libraries) or genes (e.g., genomic libraries), including, e.g., substantially all or a subsection of a chromosome or substantially all of a genome, including a human genome.
  • target elements can contain reference sequences and the like.
  • the target elements of the arrays may be ananged on the solid surface at different sizes and different densities.
  • the target element densities will depend upon a number of factors, such as the nature of the label, the solid support, and the like.
  • Each target element may comprise substantially the same nucleic acid sequences, or, a mixture of nucleic acids of different lengths and/or sequences.
  • a target element may contain more than one copy of a cloned piece of DNA, and each copy may be broken into fragments of different lengths, as described herein.
  • the length and complexity of the nucleic acid fixed onto the anay surface is not critical to the invention.
  • the array can comprise nucleic acids immobilized on a solid surface (e.g., nitrocellulose, glass, quartz, fused silica, plastics and the like). See, e.g., U.S. Patent No. 6,063,338 describing multi-well platforms comprising cycloolefin polymers if fluorescence is to be measured. [0066] In making and using the arrays and methods of the invention, known arrays and methods of making and using arrays can be incorporated in whole or in part, or variations thereof, as described, for example, in U.S. Patent Nos.
  • the present invention can be used to modify any known array, e.g., GeneChipsTM, Affymetrix, Santa Clara, CA; SpectralChipTM Mouse BAC Arrays, SpectralChipTM Human BAC Arrays and Custom Arrays of Spectral Genomics, Houston, Texas.
  • the anays of the invention can comprise housing comprising components for controlling humidity and temperature during the hybridization and wash reactions.
  • the arrays of the invention can have substrate surfaces of a rigid, semi-rigid or flexible material.
  • the substrate surface can be flat or planar, be shaped as wells, raised regions, etched trenches, pores, beads, filaments, or the like.
  • Substrates can be of any material upon which a "capture probe" can be directly or indirectly bound.
  • suitable materials can include paper, glass (see, e.g., U.S. Patent No. 5,843,767), ceramics, quartz or other crystalline substrates (e.g.
  • gallium arsenide metals, metalloids, polacryloyhnorpholide, various plastics and plastic copolymers, NylonTM, TeflonTM, polyethylene, polypropylene, poly(4-methylbutene), polystyrene, polystyrene/ latex, polymethacrylate, poly(ethylene terephthalate), rayon, nylon, poly(vinyl butyrate), polyvinylidene difluoride (PVDF) (see, e.g., U.S. Patent No. 6,024,872), silicones (see, e.g.,
  • U.S. Patent No. 6,096,817) polyformaldehyde (see, e.g., U.S. Patent Nos. 4,355,153; 4,652,613), cellulose (see, e.g., U.S. Patent No. 5,068,269), cellulose acetate (see, e.g., U.S. Patent No. 6,048,457), nitrocellulose, various membranes and gels (e.g., silica aerogels, see, e.g., U.S. Patent No. 5,795,557), paramagnetic or superparamagnetic microparticles (see, e.g., U.S. Patent No. 5,939,261) and the like.
  • various membranes and gels e.g., silica aerogels, see, e.g., U.S. Patent No. 5,795,557
  • paramagnetic or superparamagnetic microparticles see, e.g., U.S. Patent No.
  • Reactive functional groups can be, e.g., hydroxyl, carboxyl, amino groups or the like.
  • Silane e.g., mono- and dihydroxyafkylsilanes, aminoalkyltrialkoxysilanes, 3-aminopropyl-triethoxysilane, 3-ammopropyltrimethoxysilane
  • Silane can provide a hydroxyl functional group for reaction with an amine functional group.
  • the methods and compositions of the invention use biological molecules, e.g., nucleic acids, that are associated with a detectable label, e.g., have incorporated or have been conjugated to a detectable moiety.
  • a detectable label e.g., have incorporated or have been conjugated to a detectable moiety.
  • the association with the detectable moiety can be covalent or non-covalent.
  • the anay-immobilized nucleic acids and test sample nucleic acid are differentially detectable, e.g., they emit difference signals.
  • Useful labels include, e.g., 32 P, 35 S, 3 H, 14 C, 125 1, 131 I; fluorescent dyes (e.g., Cy5TM, Cy3TM, FITC, rhodamine, lanthanide phosphors, Texas red), electron-dense reagents (e.g. gold), enzymes, e.g., as commonly used in an ELISA (e.g., horseradish peroxidase, beta- galactosidase, luciferase, alkaline phosphatase), colorimetric labels (e.g. colloidal gold), magnetic labels (e.g.
  • DynabeadsTM biotin, dioxigenin, or haptens and proteins for which antisera or monoclonal antibodies are available.
  • the label can be directly incorporated into the nucleic acid or other target compound to be detected, or it can be attached to a probe or antibody that hybridizes or binds to the target.
  • a peptide can be made detectable by incorporating (e.g., into a nucleoside base) predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, transcriptional activator polypeptide, metal binding domains, epitope tags).
  • Label can be attached by spacer arms of various lengths to reduce potential steric hindrance or impact on other useful or desired properties.
  • fluors are paired together (one labeling control and another the test nucleic acid), e.g., rhodamine and fluorescein (see, e.g., DeRisi (1996) Nature Genetics 14:458-460), or lissamine-conjugated nucleic acid analogs and fluorescein- conjugated nucleotide analogs (see, e.g., Shalon (1996) supra); or Spectrum RedTM and Spectrum GreenTM (Vysis, Downers Grove, IL) or Cy3TM and Cy5TM (see below).
  • rhodamine and fluorescein see, e.g., DeRisi (1996) Nature Genetics 14:458-460
  • lissamine-conjugated nucleic acid analogs and fluorescein- conjugated nucleotide analogs see, e.g., Shalon (1996) supra); or Spectrum RedTM and Spectrum GreenTM (Vysis, Downers Grove, IL) or Cy3TM and
  • Cyanine and related dyes are particularly strongly light-absorbing and highly luminescent, see, e.g., U.S. Patent Nos. 4,337,063; 4,404,289; 6,048,982. Cy3TM and Cy5TM can be used together; both are fluorescent cyanine dyes produced by Amersham Life Sciences (Arlington Heights, IL).
  • Detectable moieties can be incorporated into array-immobilized nucleic acid and, if desired, "target" nucleic acid, by transcription (e.g., by random-primer labeling using Klenow polymerase, or "nick translation,” or, amplification, or equivalent).
  • a nucleoside base is conjugated to a detectable moiety, such as a fluorescent dye, e.g., Cy3TM or Cy5TM, and then incorporated into a nucleic acid for immobilization onto an array or for use as a sample nucleic acid.
  • a detectable moiety such as a fluorescent dye, e.g., Cy3TM or Cy5TM
  • Samples of genomic DNA can be incorporated with Cy3TM- or Cy5TM-dCTP conjugates mixed with unlabeled dCTP. According to manufacturer's instructions, if generating labeled target by PCR, a mixture of 33% modified to 66% unmodified dCTP gives maximal incorporation of label; when modified dCTP made up 50% or greater, the PCR reaction was inhibited.
  • Cy5TM is typically excited by the 633 mn line of HeNe laser, and emission is collected at 680 nm. See also, e.g., Bartosiewicz (2000) Archives of Biochem. Biophysics 376:66-73; Schena (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Pinkel (1998) Nature Genetics 20:207-211; Pollack (1999) Nature Genetics 23:41-46.
  • modified nucleotides synthesized by coupling allylamine-dUTP to the succinimidyl-ester derivatives of the fluorescent dyes or haptenes (such as biotin or digoxigenin) are used; this method allows custom preparation of most common fluorescent nucleotides, see, e.g., Henegariu (2000) Nat. Biotechnol. 18:345-348.
  • Other fluorescent nucleotide analogs can be used, see, e.g., Jameson (1997) Methods Enzymol. 278:363-390; Zhu (1994) Nucleic Acids Res. 22:3418-3422.
  • Patent Nos. 5,652,099 and 6,268,132 also describe nucleoside analogs for incorporation into nucleic acids, e.g., DNA and/or RNA, or ohgonucleotides, via either enzymatic or chemical synthesis to produce fluorescent ohgonucleotides.
  • U.S. Patent No. 5,135,717 describes phthalocyanine and tetrabenztriazaporphyrin reagents for use as fluorescent labels.
  • labeling with a detectable composition also can include a nucleic acid attached to another biological molecule, such as a nucleic acid, e.g., a nucleic acid in the form of a stem- loop structure as a "molecular beacon” or an "aptamer beacon.”
  • a nucleic acid e.g., a nucleic acid in the form of a stem- loop structure as a "molecular beacon” or an "aptamer beacon.”
  • Molecular beacons as detectable moieties are well known in the art; for example, Sokol (1998) Proc. Natl. Acad. Sci.
  • molecular beacon synthesized "molecular beacon” reporter oligodeoxynucleotides with matched fluorescent donor and acceptor chromophores on their 5' and 3' ends, h the absence of a complementary nucleic acid strand, the molecular beacon remains in a stem-loop conformation where fluorescence resonance energy transfer prevents signal emission.
  • the stem-loop structure opens increasing the physical distance between the donor and acceptor moieties thereby reducing fluorescence resonance energy transfer and allowing a detectable signal to be emitted when the beacon is excited by light of the appropriate wavelength.
  • a molecular beacon comprised of a G-rich 18-mer triplex forming oligodeoxyribonucleotide. See also U.S. Patent Nos. 6,277,581 and 6,235,504.
  • Aptamer beacons are similar to molecular beacons; see, e.g., Hamaguchi (2001) Anal. Biochem. 294:126-131; Poddar (2001) Mol. Cell. Probes 15:161-167; Kaboev (2000) Nucleic Acids Res. 28:E94.
  • Aptamer beacons can adopt two or more conformations, one of which allows ligand binding. A fluorescence-quenching pair is used to report changes in conformation induced by ligand binding. See also, e.g., Yamamoto (2000) Genes Cells 5:389-396; Smirnov (2000) Biochemistry 39:1462-1468.
  • CCDs are used in microarray scanning systems, including the multiplexed systems of the invention.
  • CCDs used in the systems and methods of the invention can scan and analyze multicolor fluorescence images; see, e.g., U.S. Patent Application Nos.
  • the methods of the invention further comprise data analysis, which can include the steps of determining, e.g., fluorescent intensity as a function of substrate position, removing "outliers" (data deviating from a predetermined statistical distribution), or calculating the relative binding affinity of the targets from the remaining data.
  • the resulting data can be displayed as an image with color in each region varying according to the light emission or binding affinity between targets and probes. See, e.g., U.S. Patent Nos. 5,324,633; 5,863,504; 6,045,996.
  • the invention can also incorporate a device for detecting a labeled marker on a sample located on a support, see, e.g., U.S. Patent No. 5,578,832.
  • immobilized and sample nucleic acids can be in a variety of lengths.
  • the biological molecule analyzed is derived from a genomic nucleic acid, and, labeled sample fragments consist of a length smaller than about 200 bases.
  • labeled genomic DNA limited to this small size significantly improves the resolution of the molecular profile analysis, e.g., in anay-based CGH.
  • use of such small fragments allows for significant suppression of repetitive sequences and other unwanted, "background" cross-hybridization on the immobilized nucleic acid.
  • the resultant fragment lengths can be modified by, e.g., treatment with DNase. Adjusting the ratio of DNase to DNA polymerase in a nick translation reaction changes the length of the digestion product. Standard nick translation kits typically generate 300 to 600 base pair fragments. If desired, the labeled nucleic acid can be further fragmented to segments below 200 bases, down to as low as about 25 to 30 bases, random enzymatic digestion of the DNA is carried out, using, e.g., a DNA endonucleases, e.g., DNase (see, e.g., Henera (1994) J. Mol. Biol. 236:405-411; Suck (1994) J. Mol. Recognit.
  • a DNA endonucleases e.g., DNase (see, e.g., Henera (1994) J. Mol. Biol. 236:405-411; Suck (1994) J. Mol. Recognit.
  • Fragment size can be evaluated by a variety of techniques, including, e.g., sizing electrophoresis, as by Siles (1997) J. Chromatogr. A. 771:319-329, that analyzed DNA fragmentation using a dynamic size-sieving polymer solution in a capillary electrophoresis. Fragment sizes can also be determined by, e.g., matrix-assisted laser desorption ionization time-of-flight mass spectrometry, see, e.g., Chiu (2000) Nucleic Acids Res. 28:E31.
  • the invention provides compositions and methods for generating molecular profiles of biological samples, e.g., nucleic acid samples, such as samples of genomic DNA or a cDNA library.
  • nucleic acid samples such as samples of genomic DNA or a cDNA library.
  • anay-bound nucleic acids are contacted with a sample comprising nucleic acids; the binding of the sample nucleic acids to the array is detected to generate a molecular profile of the sample nucleic acid.
  • the molecular profile can be a comparative genomic hybridization (CGH) reaction; detection of a genomic DNA amplification, a genomic DNA deletion, or a genomic DNA insertion; detection of a point mutation, such as identification of a single-nucleotide polymorphism (SNP); differential methylation hybridization (DMH), where the anay-bound nucleic acids are CpG island tags; detection of transcriptionally active regions of a genome (using, e.g., nuclear run-off assays); analysis of a chromatin structure; and analysis of a telomeric structure (such as telomeric erosion or telomeric addition). All of these procedures are well known in the art, and any molecular biology procedure or analysis, can be performed using the modified biological molecules or arrays of the invention. See also, co-pending United States Patent Application No. 09/853,343.
  • CGH comparative genomic hybridization
  • Comparative genomic hybridization [0082]
  • the arrays and methods of the invention are used in comparative genomic hybridization (CGH) reactions.
  • CGH is a molecular cytogenetics approach that can be used to detect regions in a genome undergoing quantitative changes, i.e. gains or losses of copy numbers.
  • Analysis of genomes of tumor cells can detect a region or regions of anomaly under going gains and/or losses.
  • Differential expression of hundreds of genes can be analyzed using a cDNA anay, thus facilitating characterization of gene expression in normal and diseased tissues.
  • Generating a molecular profile of a nucleic acid sample by comparative genomic hybridization using methods and anays of the invention can be practiced with methods and compositions known in the art, see, e.g., U.S. Patent Nos. 6,197,501; 6,159,685; 5,976,790; 5,965,362; 5,856,097; 5,830,645; 5,721,098; 5,665,549; 5,635,351; and, Diago (2001) American J. of Pathol. May;158(5):1623-1631; Theillet (2001) Bull. Cancer 88:261- 268; Werner (2001) Pharmacogenomics 2:25-36; Jain (2000) Pharmacogenomics 1:289-307.
  • the arrays and methods of the invention are used to detect point mutations, such as single-nucleotide polymorphisms (SNPs).
  • SNPs single-nucleotide polymorphisms
  • labeled nucleic acid for detecting SNPs is immobilized onto substrate surfaces.
  • Arrays can be used for high-throughput genotyping approaches for pharmacogenomics, where numerous individuals are studied with thousands of SNP markers. Generating a molecular profile of a nucleic acid sample by the analysis and detection of SNPs using methods and anays of the invention can be practiced with methods and compositions known in the art, see, e.g., U.S.
  • DH Differential methylation hybridization
  • the arrays and methods of the invention are used in differential methylation hybridization (DMH), including, for example, CpG island analysis.
  • the array-bound labeled nucleic acids comprise CpG island tags.
  • the methods and arrays of the invention are used to identify, analyze and map hypermethylated or hypomethylated regions of the genome, hi one aspect, the sample nucleic acids can comprise genomic DNA digested with at least one methylation-sensitive restriction endonuclease and the molecular profile comprises detection and mapping of hypermethylated (or hypomethylated) regions of the genome.
  • Any methylation-sensitive restriction endonuclease or equivalent endonuclease enzyme can be used, including, for example, Notl, Smal, SacJJ, Eagl, Mspl, Hpall, Sau3AI and BssHII.
  • both a methylation-sensitive enzyme and its methylation insensitive isoschizomer is used; see, e.g., Robinson (2000) Chromosome Res. 8:635-643; described use of the methylation-sensitive enzyme Hpall and its methylation insensitive isoschizomer Mspl. Windhofer (2000) Curr. Genet.
  • telomeric structure such as telomeric erosion or telomeric addition.
  • labeled nucleic acid comprising telomeric structures or, labeled telomeric structures alone, are immobilized onto substrate surfaces.
  • Telomerase assays are useful for cancer detection and diagnosis (see, e.g., Hahn (2001) Ann Med 33:123-129; Meyerson (2000) J. Clin. Oncol. 18:2626-2634; Meyerson (1998) Toxicol. Lett. 102-103:41-5).
  • telomere-based telomeric structures of the invention will accelerate understanding of telomerase biology and lead to clinically relevant telomerase-based therapies.
  • Generating a molecular profile of a nucleic acid sample by the analysis of telomeric structures using methods and arrays of the invention can be practiced with methods and compositions known in the art, see, e.g., U.S. Patent Nos. 6,221,590; 6,221,584; 6,022,709; 6,007,989; 6,004,939; 5,972,605; 5,871,926; 5,834,193; 5,830,644; 5,695,932; 5,645,986.
  • the arrays and methods of the invention are used in the analysis of chromatm structure, including chromatin condensation, chromatm decondensation, histone phosphorylation, histone acylation, and the like (see, e.g., Guo (2000) Cancer Res. 60:5667- 5672; Mahlknecht (2000) Mol. Med. 6:623-644).
  • labeled nucleic acid comprising chromatin structures, or, labeled chromatm structures alone are immobilized onto substrate surfaces. Chromatm structure remodeling occurs in certain cancers (see, e.g., Giamarchi (2000) Adv. Exp. Med. Biol. 480:155-161).
  • Chromatin structure affects nuclear processes that utilize DNA as a substrate, e.g., transcription, replication, DNA repair, and DNA organization within the nucleus. Chromatin structure analysis is useful in fertility assessment; for example, sperm with decondensed chromatm are infertile. DNA damage in patients with untreated cancer can be measured using a sperm chromatin structure assay (see, e.g., Kobayashi (2001) Fertil. Steril. 75:469-475). Generating a molecular profile of a nucleic acid sample by the analysis of chromatin structure using the methods and arrays of the invention can be practiced with methods and compositions known in the art, see, e.g., U.S. Patent Nos.
  • BAC microarrays [ 0090 ] BAC clones greater than fifty kilobases (50 kb), and up to about 300 kb, are grown up in Terrific Broth medium. Larger inserts, e.g., clones > 300 kb, and smaller inserts, about 1 to 20 kb, are also be used. DNA is prepared by a modified alkaline lysis protocol (see, e.g., Sambrook). The DNA is labeled, as described below.
  • the DNA is then chemically modified as described by U.S. Patent No. 6,048,695.
  • the modified DNA is then dissolved in proper buffer and printed directly on clean glass surfaces as described by U.S. Patent No. 6,048,695. Usually multiple spots are printed for each clone.
  • a standard random priming method is used to label genomic DNA before its attachment to the anay, see, e.g., Sambrook.
  • Sample nucleic acid is also similarly labeled.
  • Cy3TM or Cy5TM labeled nucleotides are supplemented together with corresponding unlabeled nucleotides at a molar ratio ranging from 0.0 to about 6 (unlabeled nucleotide to labeled nucleotides).
  • Labeling is carried out at 37 °C for 2 to 10 hours. After labeling the reaction mix is heated up to 95 °C to 100 °C for 3 to 5 minutes to inactivate the polymerase and denature the newly generated, labeled "probe" nucleic acid from the template.
  • the heated sample is then chilled on ice for 5 minutes.
  • "Calibrated” DNase (DNA endonuclease) enzyme is added to fragment the labeled template (generated by random priming).
  • "Trace” amounts of DNase is added (final concentration was 0.2 to 2 ng/ml; incubation time 15 to 30 minutes) to digest/ fragment the labeled nucleic acid to segments of about 30 to about 100 bases in size.

Abstract

L'invention concerne des réseaux comprenant une pluralité de molécules biologiques, chaque molécule biologique étant immobilisée sur un point connu et discret de la surface d'un substrat pour former un réseau de molécules biologiques, et chaque molécule biologique comprenant un marqueur pouvant être détecté. L'invention concerne également un système de multiplexage permettant de procéder à une hybridation génomique comparative (CGH) à l'aide d'un réseau de l'invention. L'invention concerne en outre des procédés de fabrication et d'utilisation de ces réseaux, y compris un procédé de comparaison du nombre de copies de séquences d'acides nucléiques uniques dans un échantillon.
PCT/US2002/027743 2001-08-30 2002-08-30 Reseaux comprenant des molecules biologiques pre-marquees et methodes de fabrication et d'utilisation de ces reseaux WO2003020898A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/488,492 US20050032060A1 (en) 2001-08-31 2002-08-30 Arrays comprising pre-labeled biological molecules and methods for making and using these arrays
AU2002331777A AU2002331777A1 (en) 2001-08-30 2002-08-30 Arrays comprising pre-labeled biological molecules and methods for making and using these arrays

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31634901P 2001-08-30 2001-08-30
US60/316,349 2001-08-30

Publications (2)

Publication Number Publication Date
WO2003020898A2 true WO2003020898A2 (fr) 2003-03-13
WO2003020898A3 WO2003020898A3 (fr) 2003-11-20

Family

ID=23228682

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/027743 WO2003020898A2 (fr) 2001-08-30 2002-08-30 Reseaux comprenant des molecules biologiques pre-marquees et methodes de fabrication et d'utilisation de ces reseaux

Country Status (2)

Country Link
AU (1) AU2002331777A1 (fr)
WO (1) WO2003020898A2 (fr)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066327A1 (fr) * 2004-01-08 2005-07-21 Dako Denmark A/S Appareil et methodes de traitement de prelevements biologiques, et reservoir associe
WO2005118806A2 (fr) 2004-05-28 2005-12-15 Ambion, Inc. Procedes et compositions faisant intervenir des molecules de micro-arn
WO2008036776A2 (fr) 2006-09-19 2008-03-27 Asuragen, Inc. Gènes régulés mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p et voies de signalisation utiles comme cibles dans une intervention thérapeutique
US7507539B2 (en) 2007-07-30 2009-03-24 Quest Diagnostics Investments Incorporated Substractive single label comparative hybridization
WO2010051288A1 (fr) 2008-10-27 2010-05-06 Revivicor, Inc. Ongulés immunodéprimés
EP2281888A1 (fr) 2004-11-12 2011-02-09 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
WO2011108930A1 (fr) 2010-03-04 2011-09-09 Interna Technologies Bv Molécule de miarn définie par sa source et ses utilisations thérapeutiques et en diagnostic pour maladies ou états associés à l'emt
WO2012005572A1 (fr) 2010-07-06 2012-01-12 Interna Technologies Bv Miarn et ses utilisations diagnostiques et thérapeutiques pour des maladies ou des états associés au mélanome, ou pour des maladies ou des états associés à la voie braf activée
WO2012068400A2 (fr) 2010-11-17 2012-05-24 Asuragen, Inc. Micro-arn utilisés comme biomarqueurs pour faire la distinction entre des néoplasmes thyroïdiens bénins et malins
EP2474617A1 (fr) 2011-01-11 2012-07-11 InteRNA Technologies BV MIR pour traiter une nouvelle angiogenèse
US8232055B2 (en) 2002-12-23 2012-07-31 Agilent Technologies, Inc. Comparative genomic hybridization assays using immobilized oligonucleotide features and compositions for practicing the same
EP2487240A1 (fr) 2006-09-19 2012-08-15 Asuragen, Inc. Micro ARN différemment exprimés dans des maladies pancréatiques et leurs utilisations
WO2012158238A2 (fr) 2011-02-28 2012-11-22 University Of Iowa Research Foundation Changements d'hormone antimullérienne dans la grossesse et prédiction d'évolution indésirable de grossesse et du sexe
US8321138B2 (en) 2005-07-29 2012-11-27 Agilent Technologies, Inc. Method of characterizing quality of hybridized CGH arrays
EP2527456A1 (fr) 2004-10-22 2012-11-28 Revivicor Inc. Porcs transgéniques déficients en chaîne légère d'immunoglobuline endogène
WO2013040251A2 (fr) 2011-09-13 2013-03-21 Asurgen, Inc. Méthodes et compositions incluant mir-135b, permettant de faire la distinction entre un cancer du pancréas et une maladie pancréatique bénigne
WO2013063544A1 (fr) 2011-10-27 2013-05-02 Asuragen, Inc. Miarn en tant que biomarqueurs de diagnostic pour distinguer des tumeurs thyroïdiennes bénignes de malignes
WO2013063519A1 (fr) 2011-10-26 2013-05-02 Asuragen, Inc. Procédés et compositions faisant intervenir des taux d'expression de miarn pour distinguer des kystes pancréatiques
WO2014007623A1 (fr) 2012-07-03 2014-01-09 Interna Technologies B.V. Portefeuille de diagnostic et ses utilisations
WO2014055117A1 (fr) 2012-10-04 2014-04-10 Asuragen, Inc. Micro-arn diagnostiques utilisés dans le diagnostic différentiel de lésions kystiques pancréatiques de découverte fortuite
WO2014145612A1 (fr) 2013-03-15 2014-09-18 Ajay Goel Biomarqueurs de miarn à base de tissu et de sang pour le diagnostic, le pronostic et le potentiel prédictif de métastases dans le cancer colorectal
WO2014151551A1 (fr) 2013-03-15 2014-09-25 Baylor Research Institute Marqueurs d'une néoplasie colorectale associée à la colite ulcéreuse (uc)
US8911942B2 (en) * 2004-05-20 2014-12-16 Quest Diagnostics Investments Incorporated Single label comparative hybridization
US9080215B2 (en) 2007-09-14 2015-07-14 Asuragen, Inc. MicroRNAs differentially expressed in cervical cancer and uses thereof
EP2990487A1 (fr) 2008-05-08 2016-03-02 Asuragen, INC. Compositions et procédés relatifs à la modulation de miarn de néovascularisation ou angiogenèse
WO2018082091A1 (fr) * 2016-11-07 2018-05-11 Wuhan Institute Of Virology, Chinese Academy Of Sciences Traceur transneuronal multisynaptique antérograde
EP3404116A1 (fr) 2013-03-15 2018-11-21 The University of Chicago Procédés et compositions liés à l'activité des lymphocytes t
WO2019086603A1 (fr) 2017-11-03 2019-05-09 Interna Technologies B.V. Molécule de micro-arn, équivalent, antagomir, ou source de cette molécule pour le traitement et/ou le diagnostic d'une affection et/ou d'une maladie associée à une déficience neuronale ou pour la (ré)génération neuronale
WO2020210521A2 (fr) 2019-04-12 2020-10-15 The Regents Of The University Of California Compositions et procédés d'augmentation de la masse musculaire et du métabolisme oxydatif
WO2024028794A1 (fr) 2022-08-02 2024-02-08 Temple Therapeutics BV Méthodes de traitement de troubles de l'endomètre et de l'hyperprolifération ovarienne

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807522A (en) * 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US6025136A (en) * 1994-12-09 2000-02-15 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US6027890A (en) * 1996-01-23 2000-02-22 Rapigene, Inc. Methods and compositions for enhancing sensitivity in the analysis of biological-based assays
US6037130A (en) * 1998-07-28 2000-03-14 The Public Health Institute Of The City Of New York, Inc. Wavelength-shifting probes and primers and their use in assays and kits

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807522A (en) * 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US6025136A (en) * 1994-12-09 2000-02-15 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US6027890A (en) * 1996-01-23 2000-02-22 Rapigene, Inc. Methods and compositions for enhancing sensitivity in the analysis of biological-based assays
US6037130A (en) * 1998-07-28 2000-03-14 The Public Health Institute Of The City Of New York, Inc. Wavelength-shifting probes and primers and their use in assays and kits

Cited By (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232055B2 (en) 2002-12-23 2012-07-31 Agilent Technologies, Inc. Comparative genomic hybridization assays using immobilized oligonucleotide features and compositions for practicing the same
US7901634B2 (en) 2004-01-08 2011-03-08 Dako Denmark A/S Apparatus and methods for processing biological samples and a reservoir therefor
US9133507B2 (en) 2004-01-08 2015-09-15 Dako Denmark A/S Apparatus and method for processing biological samples and a reservoir therefor
US8632739B2 (en) 2004-01-08 2014-01-21 Dakocytomation Denmark A/S Apparatus and methods for processing biological samples and a reservoir therefor
WO2005066327A1 (fr) * 2004-01-08 2005-07-21 Dako Denmark A/S Appareil et methodes de traitement de prelevements biologiques, et reservoir associe
US8211385B2 (en) 2004-01-08 2012-07-03 Dako Denmark A/S Apparatus and methods for processing biological samples and a reservoir therefor
US8911942B2 (en) * 2004-05-20 2014-12-16 Quest Diagnostics Investments Incorporated Single label comparative hybridization
EP2471921A1 (fr) 2004-05-28 2012-07-04 Asuragen, Inc. Procédés et compositions impliquant du microARN
EP2290067A2 (fr) 2004-05-28 2011-03-02 Asuragen, Inc. Procédés et compositions impliquant du microARN
US10047388B2 (en) 2004-05-28 2018-08-14 Asuragen, Inc. Methods and compositions involving MicroRNA
EP2474616A1 (fr) 2004-05-28 2012-07-11 Asuragen, Inc. Procédés et compositions impliquant du microARN
WO2005118806A2 (fr) 2004-05-28 2005-12-15 Ambion, Inc. Procedes et compositions faisant intervenir des molecules de micro-arn
EP2471924A1 (fr) 2004-05-28 2012-07-04 Asuragen, INC. Procédés et compositions impliquant du microARN
EP2290072A2 (fr) 2004-05-28 2011-03-02 Asuragen, Inc. Procédés et compositions impliquant du microARN
EP2290071A2 (fr) 2004-05-28 2011-03-02 Asuragen, Inc. Procédés et compositions impliquant du microARN
EP2290070A2 (fr) 2004-05-28 2011-03-02 Asuragen, Inc. Procédés et compositions impliquant du microARN
EP2290076A2 (fr) 2004-05-28 2011-03-02 Asuragen, Inc. Procédés et compositions impliquant du microARN
EP2290069A2 (fr) 2004-05-28 2011-03-02 Asuragen, Inc. Procédés et compositions impliquant du microARN
EP2065466A2 (fr) 2004-05-28 2009-06-03 Asuragen, Inc. Procédés et compositions impliquant du microbe
EP2290066A2 (fr) 2004-05-28 2011-03-02 Asuragen, Inc. Procédés et compositions impliquant du microARN
EP2471923A1 (fr) 2004-05-28 2012-07-04 Asuragen, Inc. Procédés et compositions impliquant du microARN
EP2290075A2 (fr) 2004-05-28 2011-03-02 Asuragen, Inc. Procédés et compositions impliquant du microARN
EP2290073A2 (fr) 2004-05-28 2011-03-02 Asuragen, Inc. Procédés et compositions impliquant du microARN
EP2290068A2 (fr) 2004-05-28 2011-03-02 Asuragen, Inc. Procédés et compositions impliquant du microARN
EP2290074A2 (fr) 2004-05-28 2011-03-02 Asuragen, Inc. Procédés et compositions impliquant du microARN
EP2471922A1 (fr) 2004-05-28 2012-07-04 Asuragen, Inc. Procédés et compositions impliquant du microARN
EP2527456A1 (fr) 2004-10-22 2012-11-28 Revivicor Inc. Porcs transgéniques déficients en chaîne légère d'immunoglobuline endogène
EP2281888A1 (fr) 2004-11-12 2011-02-09 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
US9382537B2 (en) 2004-11-12 2016-07-05 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2302054A1 (fr) 2004-11-12 2011-03-30 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
EP2302052A1 (fr) 2004-11-12 2011-03-30 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
EP2302053A1 (fr) 2004-11-12 2011-03-30 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
EP2302056A1 (fr) 2004-11-12 2011-03-30 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
EP2302051A1 (fr) 2004-11-12 2011-03-30 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
EP2302055A1 (fr) 2004-11-12 2011-03-30 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
EP2314688A1 (fr) 2004-11-12 2011-04-27 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
EP2322616A1 (fr) 2004-11-12 2011-05-18 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
EP2281886A1 (fr) 2004-11-12 2011-02-09 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
EP2284265A1 (fr) 2004-11-12 2011-02-16 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
US9506061B2 (en) 2004-11-12 2016-11-29 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US9447414B2 (en) 2004-11-12 2016-09-20 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2298894A1 (fr) 2004-11-12 2011-03-23 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
EP2808390A1 (fr) 2004-11-12 2014-12-03 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
EP2292756A1 (fr) 2004-11-12 2011-03-09 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
EP2292755A1 (fr) 2004-11-12 2011-03-09 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
EP2281887A1 (fr) 2004-11-12 2011-02-09 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
EP2298893A1 (fr) 2004-11-12 2011-03-23 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
EP2281889A1 (fr) 2004-11-12 2011-02-09 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
EP2808389A1 (fr) 2004-11-12 2014-12-03 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
US9051571B2 (en) 2004-11-12 2015-06-09 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US9068219B2 (en) 2004-11-12 2015-06-30 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2287303A1 (fr) 2004-11-12 2011-02-23 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
US8321138B2 (en) 2005-07-29 2012-11-27 Agilent Technologies, Inc. Method of characterizing quality of hybridized CGH arrays
EP2487240A1 (fr) 2006-09-19 2012-08-15 Asuragen, Inc. Micro ARN différemment exprimés dans des maladies pancréatiques et leurs utilisations
WO2008036776A2 (fr) 2006-09-19 2008-03-27 Asuragen, Inc. Gènes régulés mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p et voies de signalisation utiles comme cibles dans une intervention thérapeutique
US7892743B2 (en) 2007-07-30 2011-02-22 Quest Diagnostics Investments Incorporated Subtractive single label comparative hybridization
US7507539B2 (en) 2007-07-30 2009-03-24 Quest Diagnostics Investments Incorporated Substractive single label comparative hybridization
US9080215B2 (en) 2007-09-14 2015-07-14 Asuragen, Inc. MicroRNAs differentially expressed in cervical cancer and uses thereof
EP2990487A1 (fr) 2008-05-08 2016-03-02 Asuragen, INC. Compositions et procédés relatifs à la modulation de miarn de néovascularisation ou angiogenèse
US9365852B2 (en) 2008-05-08 2016-06-14 Mirna Therapeutics, Inc. Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
WO2010051288A1 (fr) 2008-10-27 2010-05-06 Revivicor, Inc. Ongulés immunodéprimés
WO2011108930A1 (fr) 2010-03-04 2011-09-09 Interna Technologies Bv Molécule de miarn définie par sa source et ses utilisations thérapeutiques et en diagnostic pour maladies ou états associés à l'emt
EP3214174A1 (fr) 2010-03-04 2017-09-06 InteRNA Technologies B.V. Molécule d'arnmi définie par sa source et son diagnostic et utilisations thérapeutiques dans des maladies ou des pathologies associées à l'emt
WO2012005572A1 (fr) 2010-07-06 2012-01-12 Interna Technologies Bv Miarn et ses utilisations diagnostiques et thérapeutiques pour des maladies ou des états associés au mélanome, ou pour des maladies ou des états associés à la voie braf activée
EP3369817A1 (fr) 2010-07-06 2018-09-05 InteRNA Technologies B.V. Arnmi, son diagnostic et ses usages thérapeutiques dans des maladies ou des pathologies associées à un mélanome ou dans des maladies ou pathologies associées à une voie braf activée
WO2012068400A2 (fr) 2010-11-17 2012-05-24 Asuragen, Inc. Micro-arn utilisés comme biomarqueurs pour faire la distinction entre des néoplasmes thyroïdiens bénins et malins
EP2772550A1 (fr) 2010-11-17 2014-09-03 Asuragen, Inc. Micro-ARN comme biomarqueurs pour différencier des néoplasmes de thyroïde bénins et malins
EP2474617A1 (fr) 2011-01-11 2012-07-11 InteRNA Technologies BV MIR pour traiter une nouvelle angiogenèse
WO2012096573A1 (fr) 2011-01-11 2012-07-19 Interna Technologies B.V. Miarn dans le traitement de maladies et d'états pathologiques associés à la néo-angiogenèse
WO2012158238A2 (fr) 2011-02-28 2012-11-22 University Of Iowa Research Foundation Changements d'hormone antimullérienne dans la grossesse et prédiction d'évolution indésirable de grossesse et du sexe
WO2013040251A2 (fr) 2011-09-13 2013-03-21 Asurgen, Inc. Méthodes et compositions incluant mir-135b, permettant de faire la distinction entre un cancer du pancréas et une maladie pancréatique bénigne
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
US10655184B2 (en) 2011-09-13 2020-05-19 Interpace Diagnostics, Llc Methods and compositions involving miR-135b for distinguishing pancreatic cancer from benign pancreatic disease
WO2013063519A1 (fr) 2011-10-26 2013-05-02 Asuragen, Inc. Procédés et compositions faisant intervenir des taux d'expression de miarn pour distinguer des kystes pancréatiques
WO2013063544A1 (fr) 2011-10-27 2013-05-02 Asuragen, Inc. Miarn en tant que biomarqueurs de diagnostic pour distinguer des tumeurs thyroïdiennes bénignes de malignes
WO2014007623A1 (fr) 2012-07-03 2014-01-09 Interna Technologies B.V. Portefeuille de diagnostic et ses utilisations
WO2014055117A1 (fr) 2012-10-04 2014-04-10 Asuragen, Inc. Micro-arn diagnostiques utilisés dans le diagnostic différentiel de lésions kystiques pancréatiques de découverte fortuite
EP3366785A2 (fr) 2013-03-15 2018-08-29 Baylor Research Institute Marqueurs d'une néoplasie colorectale associée à la colite ulcéreuse (uc)
WO2014145612A1 (fr) 2013-03-15 2014-09-18 Ajay Goel Biomarqueurs de miarn à base de tissu et de sang pour le diagnostic, le pronostic et le potentiel prédictif de métastases dans le cancer colorectal
EP3404116A1 (fr) 2013-03-15 2018-11-21 The University of Chicago Procédés et compositions liés à l'activité des lymphocytes t
WO2014151551A1 (fr) 2013-03-15 2014-09-25 Baylor Research Institute Marqueurs d'une néoplasie colorectale associée à la colite ulcéreuse (uc)
EP4163387A1 (fr) 2013-03-15 2023-04-12 The University of Chicago Procédés et compositions liés à l'activité des lymphocytes t
WO2018082091A1 (fr) * 2016-11-07 2018-05-11 Wuhan Institute Of Virology, Chinese Academy Of Sciences Traceur transneuronal multisynaptique antérograde
WO2019086603A1 (fr) 2017-11-03 2019-05-09 Interna Technologies B.V. Molécule de micro-arn, équivalent, antagomir, ou source de cette molécule pour le traitement et/ou le diagnostic d'une affection et/ou d'une maladie associée à une déficience neuronale ou pour la (ré)génération neuronale
WO2020210521A2 (fr) 2019-04-12 2020-10-15 The Regents Of The University Of California Compositions et procédés d'augmentation de la masse musculaire et du métabolisme oxydatif
WO2024028794A1 (fr) 2022-08-02 2024-02-08 Temple Therapeutics BV Méthodes de traitement de troubles de l'endomètre et de l'hyperprolifération ovarienne

Also Published As

Publication number Publication date
AU2002331777A1 (en) 2003-03-18
WO2003020898A3 (fr) 2003-11-20

Similar Documents

Publication Publication Date Title
WO2003020898A2 (fr) Reseaux comprenant des molecules biologiques pre-marquees et methodes de fabrication et d'utilisation de ces reseaux
US6916621B2 (en) Methods for array-based comparitive binding assays
US20090069195A1 (en) Compositions and methods for array-based nucleic acid hybridization
US6582908B2 (en) Oligonucleotides
JP5579999B2 (ja) ヒト第２０染色体の２０ｑ１３領域における新規アンプリコンおよびその使用
US20060275787A1 (en) Compositions and methods for array-based genomic nucleic acid analysis of biological molecules
AU2002330141B2 (en) Methods for detecting genetic mosaicisms using arrays
AU2002330141A1 (en) Methods for detecting genetic mosaicisms using arrays
AU742599B2 (en) Multiple functionalities within an array element and uses thereof
US20050032060A1 (en) Arrays comprising pre-labeled biological molecules and methods for making and using these arrays
US20030124542A1 (en) Methods for mapping the chromosomal loci of genes expressed by a cell
EP1586639A1 (fr) Support d'immobilisation de sonde a acide nucleique et procede de detection d'acide nucleique cible au moyen de ce support
WO2002092615A2 (fr) Compositions et methodes d'analyse d'acide nucleique genomique basee sur des jeux ordonnes d'echantillons de molecules biologiques
AU2008229872B2 (en) Compositions and methods for array-based genomic nucleic acid analysis of biological molecules
Consolandi et al. Development of oligonucleotide arrays to detect mutations and polymorphisms
AU2001263094A1 (en) Compositions and methods for array-based genomic nucleic acid analysis of biological molecules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10488492

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP